Former NIMH Director Steven Hyman warned at the STAT Summit that psychiatry lacks objective biomarkers to determine which patients will benefit from psychedelic treatments.

Bryan Johnson, rapamycin, NAD+, cellular reprogramming, biological age tests, peptides, and emerging longevity interventions.

Mind-altering substances like psilocybin, LSD, MDMA, and ayahuasca and their therapeutic and cultural use.